Delhi govt sets up panel for distribution of Amphotericin-B injection

The drug is used in the treatment of black fungus or mucormycosis and is currently in short supply

Injection for Black Fungus
Press Trust of India New Delhi
2 min read Last Updated : May 19 2021 | 1:39 PM IST

The Delhi government has set up a four-member technical expert committee (TEC) to prevent the indiscriminate use of Amphotericin-B injection and to establish a transparent and efficient system of distribution of this drug to the needy and hospitalised COVID-19 patients.

The drug is used in the treatment of black fungus or mucormycosis and is currently in short supply.

Hospitals in Delhi have reported a rise in the number of back fungus cases among people recovering from COVID-19 during the second wave and it could be ascribed to "irrational" use of steroids at home without consulting a doctor.

The expert committee will be headed by Pulmonologist Dr M K Daga, and include Dr Manisha Aggarwal, Dr S Anuradha and Dr Ravi Mehar from Maulana Azad Medical College.

All COVID hospitals requiring Amphotericin-B for treatment of patients will have to apply to the experts committee which will meet twice a day to scrutinise these applications and facilitate rapid decision making "as time is of the essence in such cases", according to an order issued by the health department.

"The guiding principles for TEC shall be evidence-based clinically approved parameters as well as principles of equity, distributive justice and transparency," the order read.

The Directorate General of Health Services should coordinate with the TEC and facilitate rapid decision making and also monitor the overall management of the drug from approval till delivery to the hospital concerned, it said.

The decision of daily meetings will be conveyed to all the stakeholders through e-mail and reasons for refusal will be written and informed to the requisitioning hospitals.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusDelhi governmentCorona Remedies

First Published: May 19 2021 | 1:27 PM IST

Next Story